These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36053931)

  • 1. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
    Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
    Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
    Zhou P; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Wang H
    Aging (Albany NY); 2020 Dec; 13(2):2365-2378. PubMed ID: 33318301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic features of Chinese small cell lung cancer.
    Liu J; Zhao Z; Wei S; Li B; Zhao Z
    BMC Med Genomics; 2022 May; 15(1):117. PubMed ID: 35596192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 7. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
    Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
    Front Oncol; 2021; 11():742833. PubMed ID: 35087742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
    Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
    Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
    Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
    Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
    Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
    Gu W; Zhuang W; Zhuang M; He M; Li Z
    Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
    Chen J; Tang Y; Liu H; Sun G; Liu H; Zhao J; Wang Z; Zhang Y; Lou F; Cao S; Qin J; Wang H; Liao B; Zeng H
    Cancer Med; 2023 Dec; 12(24):22370-22380. PubMed ID: 37986697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.